Published in Nucl Med Commun on July 01, 2005
Good clinical practice: historical background and key aspects. Nucl Med Commun (2005) 2.44
Apoptosis-detecting radioligands: current state of the art and future perspectives. Eur J Nucl Med Mol Imaging (2004) 2.21
Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med (2009) 2.17
Prediction of functional recovery after revascularization in patients with coronary artery disease and left ventricular dysfunction by gated FDG-PET. J Nucl Cardiol (2006) 1.58
188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial. J Nucl Med (2005) 1.52
Nuclear medicine asleep in sleep research? Eur J Nucl Med Mol Imaging (2002) 1.45
[11C]-DPA-713 and [18F]-DPA-714 as new PET tracers for TSPO: a comparison with [11C]-(R)-PK11195 in a rat model of herpes encephalitis. Mol Imaging Biol (2009) 1.43
Myocardial perfusion reserve in spared myocardium: correlation with infarct size and left ventricular ejection fraction. Eur J Nucl Med Mol Imaging (2013) 1.43
Phosphoramidite accelerated copper(i)-catalyzed [3 + 2] cycloadditions of azides and alkynes. Chem Commun (Camb) (2009) 1.10
PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma. J Nucl Med (2012) 1.10
Strain-promoted copper-free "click" chemistry for 18F radiolabeling of bombesin. Angew Chem Int Ed Engl (2011) 1.08
Vertebral fracture assessment in supine position: comparison by using conventional semiquantitative radiography and visual radiography. Radiology (2009) 1.07
Validation of parkinsonian disease-related metabolic brain patterns. Mov Disord (2013) 1.06
Functional imaging: where is the future? Hell J Nucl Med (2005) 1.06
PET imaging of the peripheral benzodiazepine receptor: monitoring disease progression and therapy response in neurodegenerative disorders. Curr Pharm Des (2008) 1.04
Feasibility and impact of the measurement of extracellular fluid volume simultaneous with GFR by 125I-iothalamate. Clin J Am Soc Nephrol (2008) 1.02
Assessment of neuroinflammation and microglial activation in Alzheimer's disease with radiolabelled PK11195 and single photon emission computed tomography. A pilot study. Eur Neurol (2003) 1.00
Copper-free 'click': 1,3-dipolar cycloaddition of azides and arynes. Org Biomol Chem (2008) 0.96
Prediction of functional recovery after revascularization in patients with chronic ischaemic left ventricular dysfunction: head-to-head comparison between 99mTc-sestamibi/18F-FDG DISA SPECT and 13N-ammonia/ 18F-FDG PET. Eur J Nucl Med Mol Imaging (2006) 0.94
Synthesis and preclinical evaluation of novel PET probes for P-glycoprotein function and expression. J Med Chem (2009) 0.94
The importance of left ventricular function for long-term outcome after primary percutaneous coronary intervention. BMC Cardiovasc Disord (2008) 0.94
Renal toxicity after radionuclide therapy. Radiat Res (2004) 0.93
Methotrexate reduces hippocampal blood vessel density and activates microglia in rats but does not elevate central cytokine release. Behav Brain Res (2009) 0.93
The role of indoleamine 2,3-dioxygenase in a mouse model of neuroinflammation-induced depression. J Alzheimers Dis (2012) 0.92
Evaluation of [(11)C]rofecoxib as PET tracer for cyclooxygenase 2 overexpression in rat models of inflammation. Nucl Med Biol (2007) 0.90
Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy. Eur J Nucl Med Mol Imaging (2002) 0.88
VEGF-SPECT with ¹¹¹In-bevacizumab in stage III/IV melanoma patients. Eur J Cancer (2011) 0.88
Rise in extracellular fluid volume during high sodium depends on BMI in healthy men. Obesity (Silver Spring) (2009) 0.87
Clinical relevance of left ventricular volume assessment by gated myocardial SPET in patients with coronary artery disease. Eur J Nucl Med Mol Imaging (2002) 0.86
Imaging of the 5-HT2A system: age-, gender-, and Alzheimer's disease-related findings. Neurobiol Aging (2003) 0.86
Comparison of sigma-ligands and metabolic PET tracers for differentiating tumor from inflammation. J Nucl Med (2006) 0.86
Impact of total PSA, PSA doubling time and PSA velocity on detection rates of 11C-Choline positron emission tomography in recurrent prostate cancer. World J Urol (2012) 0.86
Evaluation of [11C]-DAA1106 for imaging and quantification of neuroinflammation in a rat model of herpes encephalitis. Nucl Med Biol (2009) 0.85
Semiquantification of the peripheral-type benzodiazepine ligand [11C]PK11195 in normal human brain and application in multiple sclerosis patients. Acta Neurol Belg (2002) 0.85
Chronic stress and antidepressant treatment have opposite effects on P-glycoprotein at the blood-brain barrier: an experimental PET study in rats. J Psychopharmacol (2009) 0.84
Rapid reduction of sigma1-receptor binding and 18F-FDG uptake in rat gliomas after in vivo treatment with doxorubicin. J Nucl Med (2007) 0.84
99mTc-ciprofloxacin planar and tomographic imaging for the diagnosis of infection in the postoperative spine: experience in 48 patients. Eur J Nucl Med Mol Imaging (2004) 0.84
(99m)technetium-HYNIC(tricine/TPPTS)-Aca-bombesin(7-14) as a targeted imaging agent with microSPECT in a PC-3 prostate cancer xenograft model. Mol Pharm (2011) 0.83
Thyroidal uptake and radiation dose after repetitive I-131-MIBG treatments: influence of potassium iodide for thyroid blocking. Med Pediatr Oncol (2002) 0.83
The cholinergic system, sigma-1 receptors and cognition. Behav Brain Res (2010) 0.83
99mTc ciprofloxacin imaging for the diagnosis of infection in the postoperative spine. Nucl Med Commun (2004) 0.83
Influence of the angle of incidence on the sensitivity of gamma camera based PET. Phys Med Biol (2002) 0.83
Experimental performance assessment of SPM for SPECT neuroactivation studies using a subresolution sandwich phantom design. Neuroimage (2002) 0.82
Can celecoxib affect P-glycoprotein-mediated drug efflux? A microPET study. Nucl Med Biol (2008) 0.82
The feasibility of repeated left ventricular ejection fraction analysis with sequential single-dose radionuclide ventriculography. Nucl Med Commun (2005) 0.82
Decreased 5-HT2a receptor binding in patients with anorexia nervosa. J Nucl Med (2003) 0.81
123/125I-labelled 2-iodo-L: -phenylalanine and 2-iodo-D: -phenylalanine: comparative uptake in various tumour types and biodistribution in mice. Eur J Nucl Med Mol Imaging (2006) 0.81
Radionuclide detection of peritoneovenous shunt patency. Clin Nucl Med (2003) 0.81
Cytotoxicity of sigma-receptor ligands is associated with major changes of cellular metabolism and complete occupancy of the sigma-2 subpopulation. J Nucl Med (2008) 0.81
Synthesis and evaluation of [18F]-FEAnGA as a PET Tracer for beta-glucuronidase activity. Bioconjug Chem (2010) 0.81
In vivo evaluation and dosimetry of 123I-2-iodo-D-phenylalanine, a new potential tumor-specific tracer for SPECT, in an R1M rhabdomyosarcoma athymic mouse model. J Nucl Med (2005) 0.81
Early response of sigma-receptor ligands and metabolic PET tracers to 3 forms of chemotherapy: an in vitro study in glioma cells. J Nucl Med (2006) 0.81
Use of gated 13N-NH3 micro-PET to examine left ventricular function in rats. Nucl Med Biol (2012) 0.81
Synthesis and evaluation of 99mTc-labelled monoclonal antibody 1D09C3 for molecular imaging of major histocompatibility complex class II protein expression. Mol Imaging Biol (2011) 0.80
Incremental prognostic value of combined perfusion and function assessment during myocardial gated SPECT in patients aged 75 years or older. J Nucl Cardiol (2005) 0.79
One pot 'click' reactions: tandem enantioselective biocatalytic epoxide ring opening and [3+2] azide alkyne cycloaddition. Chem Commun (Camb) (2010) 0.79
Application of (99m)Technetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14) SPECT/CT in prostate cancer patients: a first-in-man study. Nucl Med Biol (2013) 0.79
In vivo characterization of 123/125I-2-iodo-L-phenylalanine in an R1M rhabdomyosarcoma athymic mouse model as a potential tumor tracer for SPECT. J Nucl Med (2005) 0.79
Nuclear imaging of inflammation in neurologic and psychiatric disorders. Curr Clin Pharmacol (2006) 0.79
Day-to-day variability of global left ventricular functional and perfusional measurements by quantitative gated SPECT using Tc-99m tetrofosmin in patients with heart failure due to coronary artery disease. J Nucl Cardiol (2004) 0.78
Accuracy of commercially available processing algorithms for planar radionuclide ventriculography using data for a dynamic left ventricular phantom. Nucl Med Commun (2004) 0.78
Synthesis of [18F]RGD-K5 by catalyzed [3 + 2] cycloaddition for imaging integrin αvβ3 expression in vivo. Nucl Med Biol (2013) 0.78
In vitro evaluation of 213Bi-rituximab versus external gamma irradiation for the treatment of B-CLL patients: relative biological efficacy with respect to apoptosis induction and chromosomal damage. Eur J Nucl Med Mol Imaging (2003) 0.78
Use of 11C-MPDX and PET to study adenosine A1 receptor occupancy by nonradioactive agonists and antagonists. J Nucl Med (2014) 0.78
Steroid hormones affect binding of the sigma ligand 11C-SA4503 in tumour cells and tumour-bearing rats. Eur J Nucl Med Mol Imaging (2009) 0.78
Synthesis of 99mTc-HYNIC-interleukin-12, a new specific radiopharmaceutical for imaging T lymphocytes. Eur J Nucl Med Mol Imaging (2006) 0.78
Abdominal aortic calcification detected by dual X-ray absorptiometry: A strong predictor for cardiovascular events. Ann Med (2010) 0.78
Biologic dosimetry of 188Re-HDD/lipiodol versus 131I-lipiodol therapy in patients with hepatocellular carcinoma. J Nucl Med (2004) 0.77
In vivo evaluation of [123I]-4-iodo-N-(4-(4-(2-methoxyphenyl)-piperazin-1-yl)butyl)-benzamide: a potential sigma receptor ligand for SPECT studies. Nucl Med Biol (2005) 0.77
In vitro screening for synergism of high-linear energy transfer 213Bi-radiotherapy with other therapeutic agents for the treatment of B-cell chronic lymphocytic leukemia. Cancer Biother Radiopharm (2006) 0.77
Detection of bone metastases in thyroid cancer patients: bone scintigraphy or 18F-FDG PET? Nucl Med Commun (2007) 0.76
In vivo apoptosis detection with radioiodinated Annexin V in LoVo tumour-bearing mice following Tipifarnib (Zarnestra, R115777) farnesyltransferase inhibitor therapy. Nucl Med Biol (2005) 0.76
18F-FEAnGA for PET of β-glucuronidase activity in neuroinflammation. J Nucl Med (2012) 0.76
Multimerization improves targeting of peptide radio-pharmaceuticals. Curr Pharm Des (2012) 0.76
Radiolabeling, biodistribution, and dosimetry of (123)I-mAb 14C5: a new mAb for radioimmunodetection of tumor growth and metastasis in vivo. J Nucl Med (2004) 0.76
Radiolabeled immunotherapy in non-Hodgkin's lymphoma treatment: the next step. Nucl Med Commun (2009) 0.76
Synthesis and preliminary evaluation of (S)-[11C]-exaprolol, a novel beta-adrenoceptor ligand for PET. Neurochem Int (2007) 0.76
Patient dosimetry for 131I-lipiodol therapy. Eur J Nucl Med Mol Imaging (2003) 0.76
Functional neuroimaging endpoints in drug development. Nucl Med Commun (2005) 0.76
Comparative biodistribution study of the new tumor tracer [123I]-2-iodo-L-phenylalanine with [123I]-2-iodo-L-tyrosine. Nucl Med Biol (2006) 0.76
In vivo evaluation of [18F]FEAnGA-Me: a PET tracer for imaging β-glucuronidase (β-GUS) activity in a tumor/inflammation rodent model. Nucl Med Biol (2012) 0.75
99mTc depreotide scan compared with 99mTc-MDP bone scintigraphy for the detection of bone metastases and prediction of response to hormonal treatment in patients with breast cancer. Nucl Med Commun (2004) 0.75
Nitrate administration increases blood flow in dysfunctional but viable myocardium, leading to improved assessment of myocardial viability: A PET study. J Nucl Med (2006) 0.75
Brain SPECT in sleep research. Sleep (2003) 0.75
The future of nuclear medicine. Hell J Nucl Med (2005) 0.75
Induction of β-glucuronidase release by cytostatic agents in small tumors. Mol Pharm (2012) 0.75
Growth factor/peptide receptor imaging for the development of targeted therapy in oncology. Curr Pharm Des (2008) 0.75
Myelosuppressive side-effects of radioimmunotherapy of non-Hodgkin's lymphoma: is there an increased risk? Nucl Med Commun (2005) 0.75
Clinical use of differential nuclear medicine modalities in patients with ATTR amyloidosis. Amyloid (2012) 0.75
Characteristics of a new system for monitoring the leakage factor during regional hyperthermic isolated limb perfusion. Nucl Med Commun (2011) 0.75
Good clinical practice: a plea for nuclear medicine. Nucl Med Commun (2005) 0.75
Detailed spatio-temporal solids concentration profiling during batch settling of activated sludge using a radiotracer. Water Res (2005) 0.75
Maturation of malfunctioning kidneys. Pediatr Nephrol (2005) 0.75
Impact of waiting on the perception of service quality in nuclear medicine. Nucl Med Commun (2005) 0.75
In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia. Nucl Med Biol (2008) 0.75
Left ventricular volume assessment by planar radionuclide ventriculography evaluated by MRI. Nucl Med Commun (2009) 0.75
Diagnostic pathway of integrated SPECT/CT for coronary artery disease. Eur J Nucl Med Mol Imaging (2009) 0.75
The hospital organization of the future. Nucl Med Rev Cent East Eur (2004) 0.75
Influence of farnesyl transferase inhibitor treatment on epidermal growth factor receptor status. Nucl Med Biol (2004) 0.75